ABBV AbbVie (ABBV) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001551152
Congress · 1Form 144 · 1
Insider buyers, 180 days
0
Funds added, last quarter
2,216
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $2.6M priced
What the filings say about ABBV
Insiders, 180 days
-$8.2M net sold
1 seller · 0% of sales under a 10b5-1 plan
Congress, 1 year
1 bought · 5 sold
Latest: sale, 2026-09-14
Planned sales (Form 144), 90 days
$8.2M
1 notice
AbbVie insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, AbbVie Inc. insiders sold a net $8.2M of stock across 143 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Aug 5, 2025.
- The trade is 43.9% of the 74,430 shares held after it.
- No other insider sold within 30 days.
- 2,216 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, CHIEF BUS/STRAT OFFICER Donoghoe Nicholas sold about $8.2M of ABBV on Aug 14, 2026, the largest insider sale at the company since 2025; 2,216 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 197.1% of the 2,654 shares held after it.
- 1 other insider sold within 30 days.
- 2,216 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Controller Purdue David Ryan sold about $1.2M of ABBV on Mar 4, 2026; 1 other insider sold within 30 days and 2,216 funds added in the latest 13F quarter.Context
- 15 earlier Form 4 trades (code P or S) here by this insider (15 sales), the last on Feb 25, 2026.
- The trade is 142.6% of the 7,219 shares held after it.
- 1 other insider sold within 30 days.
- 2,216 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, GC AND SECRETARY Siatis Perry C sold about $2.4M of ABBV on Mar 2, 2026; 1 other insider sold within 30 days and 2,216 funds added in the latest 13F quarter.Context
- 15 earlier Form 4 trades (code P or S) here by this insider (15 sales), the last on Feb 25, 2026.
- The trade is 56.3% of the 4,619 shares held after it.
- 1 other insider sold within 30 days.
- 2,216 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, GC AND SECRETARY Siatis Perry C sold about $611.7K of ABBV on Mar 2, 2026; 1 other insider sold within 30 days and 2,216 funds added in the latest 13F quarter.Context
- 15 earlier Form 4 trades (code P or S) here by this insider (15 sales), the last on Feb 25, 2026.
- The trade is 33.0% of the 17,510 shares held after it.
- 1 other insider sold within 30 days.
- 2,216 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, GC AND SECRETARY Siatis Perry C sold about $1.3M of ABBV on Mar 2, 2026; 1 other insider sold within 30 days and 2,216 funds added in the latest 13F quarter.143 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$8.2M over 180 days
-$8.2M over 90 days
below 83% of Pharma & Biotech
Congress
1 member bought in the last year
the lowest in Pharma & Biotech
Funds
2,216 funds bought in last quarter
the highest in Pharma & Biotech
Revenue
+8.6% year over year
more than 57% of Pharma & Biotech
Margin
6.9% net margin
more than 78% of Pharma & Biotech
Buybacks
$1.5B repurchased, FY to 2026-06-30
more than 94% of Pharma & Biotech
Short interest
0.9% of the float short (float per yahoo 2026-10-26) · 4.1 days to cover · settled 2026-09-30
below 74% of Pharma & Biotech
The situation: each line is one rule over one dataset
2 clinical trials were terminated, suspended or withdrawn in the last 90 days.
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch ABBV
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+28.4%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ABBV: institutional holders (13F)
13F holdings, latest reported quarter
149,488,412 sh
$37.6B
115,396,098 sh
$29.0B
82,596,748 sh
$20.8B
48,477,996 sh
$12.2B
47,862,796 sh
$12.2B
Congress trades in ABBV
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2026-09-14 · disclosed 4 days later
$15,001 - $50,000
Sold 2026-05-05 · disclosed 29 days later
$1,001 - $15,000
Sold 2025-12-18 · disclosed 28 days later
$1,001 - $15,000
Sold 2025-12-08 · disclosed 36 days later
$1,001 - $15,000
Sold 2025-11-13 · disclosed 28 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ABBV planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
NICHOLAS DONOGHOE
Filed 2026-08-14
$8.2M
ABBV mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Advisor Biotechnology Fund
$323.7M position · as of 2026-07-31
14.7%
Select Biotechnology Portfolio
$485.6M position · as of 2026-05-31
9.2%
Horizon Kinetics Medical ETF
$1.7M position · as of 2026-06-30
8.9%
Biotechnology Fund
$11.2M position · as of 2026-06-30
8.2%
Biotechnology Fund
$1.1M position · as of 2026-06-30
8.2%
State Street(R) Health Care Select Sector SPDR(R) ETF
$3.1B position · as of 2026-06-30
7.7%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
589 registered trials, 236 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
148
Phase 1
51 active
96
Phase 2
51 active
158
Phase 3
61 active
21
Phase 4
4 active
136
Not applicable
49 active
30
Multi-phase
20 active
What changed recently
A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Comb
2026-10-22 · Active Not Recruiting → Terminated · Strategic considerations
Phase 1
A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab
2026-10-21 · Not Yet Recruiting → Recruiting
Phase 3
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentam
2026-10-20 · Completion moved 2040-09 → 2041-03
PHASE2,PHASE3
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Liv
2026-10-20 · Recruiting → Active Not Recruiting
PHASE2,PHASE3
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Sub
2026-10-17 · Completion moved 2027-06 → 2031-01
Phase 3
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Sub
2026-10-17 · Recruiting → Active Not Recruiting
Phase 3
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Abbvie Political Action Committee
Cycle 2026 · $1,057K spent
$1.2M
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return · Michael
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$32.5M
$57.4M
$12.1M
+159%
+87%
2023
$25.7M
$34.7M
$12.3M
+64%
+43%
2022
$26.3M
$67.4M
$9.1M
+64%
+33%
2021
$23.9M
$66.4M
$11.0M
+32%
+23%
2020
$24.0M
$47.0M
$15.2M
+28%
+9%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $8.2M sold by insiders over 180 days, 2,216 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade, $8.2M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
ABBV financials
Revenue growth
+8.6%
XBRL, annual
Net margin
6.9%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$64.4B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM ABBV
| FY Dec 2025 | $61.2B |
| FY Dec 2024 | $56.3B |
| FY Dec 2023 | $54.3B |
| FY Dec 2022 | $58.1B |
| FY Dec 2021 | $56.2B |
| Jun 2026 | $17.0B |
| Mar 2026 | $15.0B |
| Dec 2025 | $16.6B |
| Sep 2025 | $15.8B |
| Jun 2025 | $15.4B |
| Mar 2025 | $13.3B |
| Dec 2024 | $15.1B |
| Sep 2024 | $14.5B |
At each fiscal year end
Single quarter
Net margin, TTM
+9.8%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM ABBV
| FY Dec 2025 | +6.9% |
| FY Dec 2024 | +7.6% |
| FY Dec 2023 | +9.0% |
| FY Dec 2022 | +20.4% |
| FY Dec 2021 | +20.5% |
| Jun 2026 | +21.3% |
| Mar 2026 | +4.6% |
| Dec 2025 | +10.9% |
| Sep 2025 | +1.2% |
| Jun 2025 | +6.1% |
| Mar 2025 | +9.6% |
| Dec 2024 | -0.1% |
| Sep 2024 | +10.8% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$18.2B
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM ABBV
| FY Dec 2025 | $17.8B |
| FY Dec 2024 | $17.8B |
| FY Dec 2023 | $22.1B |
| FY Dec 2022 | $24.2B |
| FY Dec 2021 | $22.0B |
| Jun 2026 | $3.1B |
| Mar 2026 | $3.6B |
| Dec 2025 | $4.9B |
| Sep 2025 | $6.6B |
| Jun 2025 | $4.9B |
| Mar 2025 | $1.4B |
| Dec 2024 | $6.8B |
| Sep 2024 | $5.2B |
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity ABBV
| FY Dec 2025 | n/a |
| FY Dec 2024 | 20.10x |
| FY Dec 2023 | 5.72x |
| FY Dec 2022 | 3.66x |
| FY Dec 2021 | 4.93x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | 46.56x |
| Dec 2024 | 20.10x |
| Sep 2024 | 9.70x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.31x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt ABBV
| FY Dec 2025 | 0.28x |
| FY Dec 2024 | 0.28x |
| FY Dec 2023 | 0.39x |
| FY Dec 2022 | 0.40x |
| FY Dec 2021 | 0.30x |
| Jun 2026 | 0.31x |
| Mar 2026 | 0.33x |
| Dec 2025 | 0.28x |
| Sep 2025 | 0.31x |
| Jun 2025 | 0.28x |
| Mar 2025 | 0.25x |
| Dec 2024 | 0.28x |
| Sep 2024 | 0.28x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity ABBV
| FY Dec 2025 | +15,367% |
| FY Dec 2024 | +62.5% |
| FY Dec 2023 | +35.2% |
| FY Dec 2022 | +72.5% |
| FY Dec 2021 | +81.0% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | +15,367% |
| Sep 2025 | +140.9% |
| Jun 2025 | +114.1% |
| Mar 2025 | +89.0% |
| Dec 2024 | +62.5% |
| Sep 2024 | +56.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+4.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets ABBV
| FY Dec 2025 | +3.1% |
| FY Dec 2024 | +3.2% |
| FY Dec 2023 | +3.6% |
| FY Dec 2022 | +8.3% |
| FY Dec 2021 | +7.8% |
| Jun 2026 | +4.6% |
| Mar 2026 | +2.7% |
| Dec 2025 | +3.1% |
| Sep 2025 | +1.7% |
| Jun 2025 | +2.7% |
| Mar 2025 | +2.9% |
| Dec 2024 | +3.2% |
| Sep 2024 | +3.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+23.2%
operating income after a 27.4% effective tax rate, over long-term 2026-06-30 plus current 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital ABBV
| FY Dec 2025 | +15.7% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | +16.0% |
| FY Dec 2022 | +22.8% |
| FY Dec 2021 | +19.6% |
| Jun 2026 | +23.2% |
| Mar 2026 | +17.1% |
| Dec 2025 | +15.7% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | +17.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+17.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed ABBV
| FY Dec 2025 | +16.1% |
| FY Dec 2024 | +9.5% |
| FY Dec 2023 | +12.4% |
| FY Dec 2022 | +16.4% |
| FY Dec 2021 | +15.4% |
| Jun 2026 | +17.7% |
| Mar 2026 | +15.8% |
| Dec 2025 | +16.1% |
| Sep 2025 | +9.3% |
| Jun 2025 | +11.1% |
| Mar 2025 | +9.7% |
| Dec 2024 | +9.5% |
| Sep 2024 | +13.7% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
81.00x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing ABBV
| FY Dec 2025 | 96.82x |
| FY Dec 2024 | 74.04x |
| FY Dec 2023 | 56.77x |
| FY Dec 2022 | 24.45x |
| FY Dec 2021 | 20.99x |
| Jun 2026 | 71.08x |
| Mar 2026 | 107.14x |
| Dec 2025 | 96.82x |
| Sep 2025 | 175.41x |
| Jun 2025 | 88.39x |
| Mar 2025 | 89.16x |
| Dec 2024 | 74.04x |
| Sep 2024 | 68.57x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$562.6B
market value at close 2026-10-26 on 2026-07-27 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value ABBV
| FY Dec 2025 | $465.6B |
| FY Dec 2024 | $375.3B |
| FY Dec 2023 | $320.0B |
| FY Dec 2022 | $339.7B |
| FY Dec 2021 | $305.6B |
| Jun 2026 | $500.5B |
| Mar 2026 | $439.7B |
| Dec 2025 | $465.6B |
| Sep 2025 | $470.2B |
| Jun 2025 | $389.9B |
| Mar 2025 | $430.8B |
| Dec 2024 | $375.3B |
| Sep 2024 | $400.1B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+3.6%
TTM free cash flow over market value at close 2026-10-26
FCF yield ABBV
| FY Dec 2025 | +4.4% |
| FY Dec 2024 | +5.7% |
| FY Dec 2023 | +8.1% |
| FY Dec 2022 | +8.5% |
| FY Dec 2021 | +9.2% |
| Jun 2026 | +4.1% |
| Mar 2026 | +5.2% |
| Dec 2025 | +4.4% |
| Sep 2025 | +4.8% |
| Jun 2025 | +5.6% |
| Mar 2025 | +4.2% |
| Dec 2024 | +5.7% |
| Sep 2024 | +4.5% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
1.18x
P/E over trailing EPS growth of 69%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing ABBV
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 9.86x |
| FY Dec 2021 | 0.17x |
| Jun 2026 | 1.04x |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $61.2B | $56.3B | $54.3B | $58.1B |
| Operating income | $15.1B | $9.1B | $12.8B | $18.1B |
| Net income | $4.2B | $4.3B | $4.9B | $11.8B |
| EPS (diluted) | 2.36 | 2.39 | 2.72 | 6.63 |
| Operating cash flow | $19.0B | $18.8B | $22.8B | $24.9B |
| Cash | $5.2B | $5.5B | $12.8B | $9.2B |
| Long-term debt | $64.5B | $66.8B | $59.2B | $63.1B |
| Buybacks | $980.0M | $1.7B | $2.0B | $1.5B |
| Dividends paid | $11.7B | $11.0B | $10.5B | $10.0B |
SEC XBRL, fiscal years, as known on 2026-10-27
ABBV Stock Sonar score 6/7 axes
Find similar shapesCompareABBV ranks highest on financial health (85th percentile) and profitability (82nd), and lowest on insider conviction (8th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ABBV filings, in plain words
Are AbbVie insiders buying or selling ABBV?
In the 180 days to 2026-10-27, AbbVie insiders were net sellers, a net $8.2M across purchases and sales reported on Form 4, by 1 seller.
Have members of Congress traded ABBV?
Yes. In the year to 2026-10-27, 1 House member disclosed buying ABBV and 5 House members disclosed selling it; the latest on record is a sale by Pete Sessions dated 2026-09-14.
Are there planned insider sales of ABBV?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-27, covering $8.2M of stock; the latest, by NICHOLAS DONOGHOE, was filed 2026-08-14.
Read the full summary
In the 180 days to 2026-10-27, AbbVie insiders were net sellers of ABBV, a net $8.2M across purchases and sales reported on Form 4 by 1 seller. In the year to 2026-10-27, 1 member of Congress disclosed buying ABBV and 5 members disclosed selling it; the latest on record is a sale by Pete Sessions dated 2026-09-14. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-27, covering $8.2M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
